Anthropic plans IPO, suggests AI can help cure cancer

Anthropic, the company behind the Claude chatbot, is preparing to go public and has announced its intention to use artificial intelligence to help cure diseases, such as cancer, and stimulate global economies. The company filed documents with the US Securities and Exchange Commission for an initial public offering, intending to list on the Nasdaq under the symbol ANT.

The IPO is expected to be one of the largest and most prestigious in the world, although the number of shares to be sold and the estimated price have yet to be disclosed. The prospectus outlines Anthropic's growth strategy and potential risks for investors. The AI company believes AI is one of the most transformative technologies in human history, with the potential to enhance the quality of life and accelerate scientific progress, including finding cures for diseases like cancer, Alzheimer's, heart disease, and rare genetic disorders.

However, the prospectus also acknowledges potential risks, such as societal disruptions, misuse, and existential threats, including cyber attacks. Anthropic reported a net loss of $80.7 billion in the first half of 2026, compared to $13 billion in the same period last year, but revenues have grown substantially to $16.3 billion, up from $41 million in 2023.

Meanwhile, Meta, the parent company of Facebook and Instagram, plans to raise around $95 billion through stock offerings to fuel further investments in AI, including projects in personal superintelligence, consumer and business agents, enterprise products, and AI glasses.